Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Semin Diagn Pathol. 2021 May;38(3):167-174. doi: 10.1053/j.semdp.2021.03.003. Epub 2021 Mar 15.
The SWItch/Sucrose Non-Fermentable (SWI/SNF) complexes are ubiquitous ATP dependent chromatin remodeling complexes that provide epigenetic regulation of gene expressions across the genome. Different combination of SWI/SNF subunits allow tissue specific regulation of critical cellular processes. The identification of SMARCB1 inactivation in pediatric malignant rhabdoid tumors provided the first example that the SWI/SNF complex may act as a tumor suppressor. It is now estimated at least 20% of all human tumors contain mutations in the subunits of the SWI/SNF complex. This review summarizes the central nervous system tumors with alterations in the SWI/SNF complex genes. Atypical teratoid/rabdoid tumor (AT/RT) is a highly aggressive embryonal tumor genetically characterized by bi-allelic inactivation of SMARCB1, and immunohistochemically shows complete absence of nuclear expression of its protein product INI1. A small subset of AT/RT show retained INI1 expression but defects in another SWI/SNF complex gene SMARCA4. Embryonal tumors with medulloblastoma, pineoblastoma, or primitive neuroectodermal morphology but loss of INI1 expression are now classified as AT/RT. Cribriform neuroepithelial tumor (CRINET) is an intra or para-ventricular tumor that has similar SMARCB1 alterations as AT/RT but generally has a benign clinical course. Besides AT/RT and CRINET, compete loss of nuclear INI1 expression has also been reported in poorly differentiated chordoma and intracranial myxoid sarcoma within the central nervous system. Families with non-truncating SMARCB1 mutations are prone to develop schwannomatosis and a range of developmental syndromes. The schwannomas in these patients usually demonstrate a mosaic INI1 staining pattern suggestive of partial residual protein function. Finally, clear cell meningioma is a WHO grade II variant meningioma characterized by bi-allelic inactivation of the SMARCE1 gene and immunohistochemically show loss of its protein product BAF57 expression in tumor cell nuclei.
SWItch/Sucrose Non-Fermentable (SWI/SNF) 复合物是普遍存在的 ATP 依赖性染色质重塑复合物,可在整个基因组中提供基因表达的表观遗传调控。不同的 SWI/SNF 亚基组合允许组织特异性调节关键的细胞过程。在小儿恶性横纹肌样瘤中发现 SMARCB1 失活,首次表明 SWI/SNF 复合物可能作为肿瘤抑制因子发挥作用。现在估计至少有 20%的人类肿瘤存在 SWI/SNF 复合物亚基的突变。本综述总结了中枢神经系统肿瘤中 SWI/SNF 复合物基因的改变。非典型畸胎瘤/横纹肌样瘤(AT/RT)是一种高度侵袭性的胚胎肿瘤,遗传特征为 SMARCB1 的双等位基因失活,免疫组化显示其蛋白产物 INI1 的核表达完全缺失。一小部分 AT/RT 显示保留的 INI1 表达,但另一个 SWI/SNF 复合物基因 SMARCA4 存在缺陷。具有髓母细胞瘤、松果体瘤或原始神经外胚层形态但缺乏 INI1 表达的胚胎肿瘤现在被归类为 AT/RT。筛状神经上皮瘤(CRINET)是一种位于脑室内或脑室外的肿瘤,具有与 AT/RT 相似的 SMARCB1 改变,但通常具有良性的临床病程。除了 AT/RT 和 CRINET 外,在中枢神经系统内的低分化脊索瘤和颅内黏液肉瘤中也有报道完全丧失核 INI1 表达。非截断 SMARCB1 突变的家族易患神经鞘瘤病和一系列发育综合征。这些患者的神经鞘瘤通常表现出马赛克 INI1 染色模式,提示部分残留蛋白功能。最后,透明细胞脑膜瘤是一种 WHO 分级 II 型脑膜瘤,其特征是 SMARCE1 基因的双等位基因失活,免疫组化显示肿瘤细胞核内其蛋白产物 BAF57 的表达缺失。